Concepedia

Samuel Cytryn

SC

6

Publications

154

Citations

6

H-Index

2019

Active since

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Cornell University

Columbia University Irving Medical Center

Samuel Cytryn is an author at Memorial Sloan Kettering Cancer Center specializing in surgery, pharmacotherapy, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2019–2024

6

Publications

6

First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial

Samuel Cytryn, Ryan H. Moy, Darren Cowzer et al. · The Lancet Oncology · 2023 · 39 citations · Full text

, , +9

Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis

Elizaveta Efuni, Samuel Cytryn, Patrick M. Boland et al. · JCR Journal of Clinical Rheumatology · 2020 · 38 citations · Full text

Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure

Emily C. Ayers, Shaoying Li, L. Jeffrey Medeiros et al. · Cancer · 2019 · 35 citations · Full text

PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays

Samuel J. Klempner, Eric S Cowden, Samuel Cytryn et al. · JCO Precision Oncology · 2024 · 20 citations

Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial

Lingyun Sun, Yun Xu, Nan Chen et al. · European Journal of Cancer · 2024 · 12 citations · Full text

Rows per page

1–5 of 6